Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study

Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study

Background: Apremilast, an oral phosphodiesterase 4 inhibitor, is approved in the European Union for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients refractory or contraindicated to or intolerant of other systemic therapies. Objectives: The APPRECIATE study assessed ap...

Full description

Bibliographic Details
Main Authors: Constanze Jonak, Isolde Göttfried, Sylvia Perl-Convalexius, Barbara Gruber, Martina Schütz-Bergmayr, Igor Vujic, Wolfgang Weger, Nikolaus Schicher, Lydia Semlin, Margit Hemetsberger, Myriam Cordey, Paul Sator
Format: Article
Language:English
Published: SAGE Publishing 2023-02-01
Series:Therapeutic Advances in Chronic Disease
Online Access:https://doi.org/10.1177/20406223231152785

Internet

https://doi.org/10.1177/20406223231152785

Similar Items